Research programme: immunotherapeutics - BioArctic NeuroscienceAlternative Names: AD-0802; AD-1502; AD-2203; AE-1501; BAN-0805; BAN-2203; BAN-2502; PD-0805
Latest Information Update: 22 Sep 2016
At a glance
- Originator BioArctic Neuroscience
- Class Monoclonal antibodies; Vaccines
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease